Pulmonary fibrosis is a patchy, focal process that begins in the alveolus. Repair following insults which induce fibrosis is critically dependent on alveolar epithelial cell (AEC) reconstitution in the injured alveolus. Chronic inflammatory cells provide crucial signals to both AEC and fibroblasts during the processes that repair the alveolar wall. We believe that chemokine receptor-2 (CCR2) is crucial to the maintenance of a homeostatic balance between regenerative and fibrotic alveolar responses. Hypothesis: CCR2 activation promotes a pathologic fibrotic response by turning off local expression of molecules that otherwise would support normal repair. In the absence of CCR2 activation, AEC and alveolar macrophages (AMO) at the site of injury display a phenotype that supports repair, with local expression of GM-CSF, PGE2 and IFN to limit fibrosis. In the presence of CCR2 activation, local expression of these protective factors is reduced, resulting in decreased NEC proliferation, increased AEC apoptosis and increased matrix deposition. This hypothesis will be addressed using a model in which a single intratracheal challenge with fluorescein isothiocyanate (FITC) leads to chronic inflammation and patchy, focal pulmonary fibrosis in areas initially involved in injury. The pulmonary fibroproliferative response is persistent and does not spontaneously regress. CCR2 expressing mice (CCR2 +/+) and mice which lack CCR2 (CCR2 -/-) will be utilized. We will determine the kinetics and sites of expression of CCR2, IFNy, GM-CSF and the enzymes responsible for PGE2 synthesis. We will determine the effects of CCR2 and GM-CSF on AEC proliferation and apoptosis in FITC-induced pulmonary fibrosis. The roles of IFN and PGE2 as mediators of enhanced repair in CCR2 -/- mice will be determined. Regulation of CCR2 expression on AMO and murine AEC will be explored. Finally, the effects of GM-CSF and MCP-1 on Al,.C synthesis of PGE2 will be determined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL056402-06
Application #
6565048
Study Section
Project Start
2001-12-26
Project End
2006-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
6
Fiscal Year
2002
Total Cost
$208,827
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schmidt, S L; Nambiar, A M; Tayob, N et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176-83
Trujillo, Glenda; Meneghin, Alessia; Flaherty, Kevin R et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2:57ra82
Fell, Charlene D; Martinez, Fernando J; Liu, Lyrica X et al. (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:832-7
Huang, Steven K; White, Eric S; Wettlaufer, Scott H et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:4317-26
Fell, Charlene D; Liu, Lyrica Xiaohong; Motika, Caroline et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:402-7
Huang, Steven K; Peters-Golden, Marc (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442-50
Han, M K; Murray, S; Fell, C D et al. (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183-8
Muro, Andres F; Moretti, Federico A; Moore, Bethany B et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638-45
Huang, Steven K; Wettlaufer, Scott H; Hogaboam, Cory M et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 177:66-74
Meneghin, A; Choi, E S; Evanoff, H L et al. (2008) TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 130:979-92

Showing the most recent 10 out of 96 publications